Rituximab as 'first choice' showed no clear difference in mortality measured by clinical assessment over 28 months compared with placebo (low certainty).
The review found no eligible studies for this question.
Rituximab as 'switching' may leads to lower relapse measured by clinical assessment over 12 months compared with placebo (low certainty).
It is very uncertain whether rituximab as 'switching' changes serious adverse events measured by clinical assessment over 12 months compared with placebo (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether rituximab as 'switching' changes common infections measured by clinical assessment over 12 months compared with placebo (very low certainty).
It is very uncertain whether rituximab as 'switching' changes cancer measured by clinical assessment over 12 months compared with placebo (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether rituximab as 'switching' changes mortality measured by clinical assessment over 12 months compared with placebo (very low certainty).
It is very uncertain whether rituximab as 'switching' changes interferons or glatiramer acetate compared with other disease‐modifying treatments (very low certainty).
Rituximab as 'switching' probably leads to lower fingolimod compared with other disease‐modifying treatments (moderate certainty).
It is very uncertain whether rituximab as 'switching' changes natalizumab compared with other disease‐modifying treatments (very low certainty).
Rituximab as 'switching' probably leads to higher interferon beta or glatiramer acetate compared with other disease‐modifying treatments (moderate certainty).
It is very uncertain whether rituximab as 'switching' changes ocrelizumab compared with other disease‐modifying treatments (very low certainty).
Rituximab as 'first choice' showed no clear difference in dimethyl fumarate compared with other disease‐modifying treatments (low certainty).
Rituximab as 'first choice' showed no clear difference in disability worsening measured by EDSS over 24 months compared with placebo (moderate certainty).
Rituximab as 'first choice' showed no clear difference in relapse measured by clinical assessment over 24 months compared with placebo (low certainty).
Rituximab as 'first choice' showed no clear difference in serious adverse events measured by clinical assessment over 28 months compared with placebo (low certainty).
It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with vitamin K antagonist (VKA) (very low certainty).
The review found no eligible studies for this question.